KDNY Chinook Therapeutics Inc

Price (delayed)

$12.15

Market cap

$544.32M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$6.56

Enterprise value

$447.2M

Chinook Therapeutics, Inc. is a clinical-stage biotechnology company developing precision medicines for kidney diseases. Chinook's product candidates are being investigated in rare, severe chronic kidney disorders with opportunities for well-defined ...

Highlights
Chinook Therapeutics's EPS has soared by 75% YoY and by 12% from the previous quarter
The revenue has dropped by 107% year-on-year
Chinook Therapeutics's gross profit has plunged by 107% YoY

Key stats

What are the main financial stats of KDNY
Market
Shares outstanding
44.8M
Market cap
$544.32M
Enterprise value
$447.2M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
1.83
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
-$18.31M
EBIT
-$134.28M
EBITDA
-$129.25M
Free cash flow
-$84.2M
Per share
EPS
-$6.56
Free cash flow per share
-$1.92
Book value per share
$6.65
Revenue per share
-$0.42
TBVPS
$8.26
Balance sheet
Total assets
$407.87M
Total liabilities
$111.14M
Debt
$40.43M
Equity
$296.73M
Working capital
$179.56M
Liquidity
Debt to equity
0.14
Current ratio
8.55
Quick ratio
8.4
Net debt/EBITDA
0.75
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-37%
Return on equity
-56.8%
Return on invested capital
-66.5%
Return on capital employed
-35%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

KDNY stock price

How has the Chinook Therapeutics stock price performed over time
Intraday
-0.16%
1 week
-1.14%
1 month
-2.57%
1 year
-23.97%
YTD
-23.39%
QTD
-4.78%

Financial performance

How have Chinook Therapeutics's revenue and profit performed over time
Revenue
-$18.31M
Gross profit
-$18.31M
Operating income
-$102.16M
Net income
-$137.22M
Gross margin
N/A
Net margin
N/A
The revenue has dropped by 107% year-on-year
Chinook Therapeutics's gross profit has plunged by 107% YoY
Chinook Therapeutics's operating income has plunged by 53% from the previous quarter
KDNY's net income is down by 34% since the previous quarter

Growth

What is Chinook Therapeutics's growth rate over time

Valuation

What is Chinook Therapeutics stock price valuation
P/E
N/A
P/B
1.83
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Chinook Therapeutics's EPS has soared by 75% YoY and by 12% from the previous quarter
KDNY's price to book (P/B) is 39% less than its last 4 quarters average of 3.0 and 37% less than its 5-year quarterly average of 2.9
The revenue has dropped by 107% year-on-year

Efficiency

How efficient is Chinook Therapeutics business performance
KDNY's ROIC is down by 25% from the previous quarter
The return on assets has declined by 21% since the previous quarter
KDNY's return on equity is down by 20% year-on-year

Dividends

What is KDNY's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for KDNY.

Financial health

How did Chinook Therapeutics financials performed over time
The total assets has soared by 54% YoY and by 2.3% QoQ
The total liabilities has contracted by 49% YoY but it has grown by 13% from the previous quarter
Chinook Therapeutics's debt is 86% lower than its equity
The debt to equity has dropped by 80% year-on-year
Chinook Therapeutics's debt has increased by 24% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.